TheBrief.Health

From Terminal to Chronic: 7-Year Follow-Up Data from the CROWN Study

Episode Summary

This review examines 7-year CROWN trial data showing lorlatinib’s unprecedented durability in ALK-positive NSCLC, highlighting survival gains, CNS protection, resistance suppression, and toxicity management.